Mirnia Kayvan, Haji Esmaeil Memar Elmira, Kamran Niyoosha, Yeganedoost Saadollah, Nickhah Klashami Zeynab, Mamishi Setareh, Mahmoudi Shima
Department of Neonatology, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Sci Rep. 2024 Feb 19;14(1):4086. doi: 10.1038/s41598-024-54450-w.
Since the initiation of the COVID-19 vaccination effort, there has been widespread concern regarding vaccine efficacy and potential side effects. This study aimed to explore the short-term side effects of four available COVID-19 vaccines (Sputnik V, Sinopharm, Oxford-AstraZeneca, and Covaxin) among healthcare workers (HCWs) in Iran. The multicenter study involved 1575 HCWs, with the majority received Sputnik V (74.1%), followed by Covaxin (15.6%), Sinopharm (6.4%), and Oxford-AstraZeneca (3.8%). The prevalence of at least one side effect after the first and second dose COVID-19 vaccine was 84.6% and 72.9%, respectively. The common side effects (presented in > 50% of the study participants) after the first dose of the vaccine were injection site pain (61.7%), myalgia (51.8%), and muscle pain (50.9%). The most reported side effects after the second dose of the vaccine were injection site pain (26.8%), myalgia (15.8%), fever (10.3%), headache (9.9%), and chills (9.2%). In conclusion, according to the COVID-19 vaccine type, different side effects might occur following the first and second doses of vaccination. These findings assist in addressing the ongoing problems of vaccination hesitancy which has been driven by widespread worries about the vaccine safety profile.
自启动新冠疫苗接种工作以来,人们对疫苗效力和潜在副作用普遍感到担忧。本研究旨在探讨四种可用的新冠疫苗(卫星五号、国药集团、牛津-阿斯利康和科瓦克辛)在伊朗医护人员中的短期副作用。这项多中心研究涉及1575名医护人员,其中大多数接种了卫星五号(74.1%),其次是科瓦克辛(15.6%)、国药集团(6.4%)和牛津-阿斯利康(3.8%)。接种第一剂和第二剂新冠疫苗后至少出现一种副作用的比例分别为84.6%和72.9%。接种第一剂疫苗后常见的副作用(在超过50%的研究参与者中出现)是注射部位疼痛(61.7%)、肌痛(51.8%)和肌肉疼痛(50.9%)。接种第二剂疫苗后报告最多的副作用是注射部位疼痛(26.8%)、肌痛(15.8%)、发热(10.3%)、头痛(9.9%)和寒战(9.2%)。总之,根据新冠疫苗的类型,接种第一剂和第二剂疫苗后可能会出现不同的副作用。这些发现有助于解决因对疫苗安全性普遍担忧而导致的疫苗接种犹豫这一持续存在的问题。